RespireRx Pharmaceuticals Inc. to Present at 10th Annual Biotech Showcase™ 2018
January 08, 2018 08:45 ET
|
RespireRX Pharmaceuticals Inc.
CEO to Review completed Phase IIB dronabinol trial for the treatment of Obstructive Sleep Apnea (OSA) and Provide Pipeline update Glen Rock, N.J., Jan. 08, 2018 (GLOBE NEWSWIRE) -- RespireRx...
RespireRx Pharmaceuticals Inc. Publishes Compelling Scientific Evidence Demonstrating the Neurobiological Safety of Ampakine CX717 and Justifying Continued Clinical Development
December 18, 2017 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Dec. 18, 2017 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that a paper detailing the neurobiologic safety...
RespireRx Pharmaceuticals Inc. Officers and Directors Elect to Forgive $2,356,733 of Past Due Cash Compensation and Receive Non-Qualified Stock Options to Reduce Balance Sheet Debt
December 15, 2017 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Dec. 15, 2017 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of...
RespireRx Pharmaceuticals Inc. Announces Publication of Phase 2B PACE Study: Once per Night Treatment with Dronabinol Provides Statistically Significant Improvement in Clinical Measures of Obstructive Sleep Apnea
November 30, 2017 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J, Nov. 30, 2017 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”) announces that the results of the PACE (Pharmacotherapy of Apnea by...